Bayer-bought BlueRock cuts 12% of workforce across 3 sites as pipeline contracts

BlueRock Therapeutics is shrinking its pipeline to afford growing clinical plans, including an upcoming phase 2 Parkinson’s disease trial, laying off 12% of the team across three sites.